Skip to main content
News Icon

Publication

Nature Publication by Heneka and colleagues

Inflammatory Processes Drive Progression of Alzheimer's and Other Brain Diseases

Report in "Nature" Inflammation drives the progression of neurodegenerative brain diseases and plays a major role in the accumulation of tau proteins within neurons. An international research team led by Prof. Michael Heneka (DZNE), member of cluster of excellence ImmunoSensation, and the University of Bonn comes to this conclusion in the journal "Nature". The findings are based on the analyses of human brain tissue and further lab studies. In the particular case of Alzheimer's the results reveal a hitherto unknown connection between Abeta and tau pathology. Furthermore, the results indicate that inflammatory processes represent a potential target for future therapies. ies. In the particular case of Alzheimer's the results reveal a hitherto unknown connection between Abeta and tau pathology. Furthermore, the results indicate that inflammatory processes represent a potential target for future therapies.

Publication

NLRP3 inflammasome activation drives tau pathology

Christina Ising et al., Nature (2019), DOI: 10.1038/s41586-019-1769-z

Related news

Dr. Clivia Lisowski und Prof. Christian Kurts

Publication

Immune cells in the liver help pigeons navigate

—How do pigeons find their way home safely over distances of many kilometers? A research team from the University Hospital Bonn (UKB), the University of Bonn, the University of Duisburg-Essen, and the Max Planck Institute for Behavioral Biology has now discovered a previously unknown mechanism: specific immune cells in the liver may help the birds detect the Earth’s magnetic field. The findings have now been published in the journal Science.
View entry
News Icon

Publication

Twin Lancet Publications Highlight Promising New Approach for Lupus Treatment

—A team of international researchers, including ImmunoSensation³ member Prof. Jörg Wenzel, reports promising phase 2 results for enpatoran, a first-in-class oral TLR7/8 inhibitor, in patients with cutaneous and systemic lupus erythematosus (CLE/SLE). In the WILLOW trial, enpatoran significantly improved skin disease activity in a dose-dependent manner and showed favourable safety outcomes. In systemic SLE, treatment also reduced global disease activity and rapidly suppressed the type I interferon gene signature. The twin studies were published in The Lancet and The Lancet Rheumatology.
View entry
Wissenschaftler

Publication

Driver of inflammation after mild head injury

—Mild traumatic brain injuries can lead to persistent memory problems and an increased risk of dementia. Yet, effective therapies to counteract these long-term consequences are still lacking. Dr. Dr. Sergio Castro-Gomez, Early Career Research Group Leader at the Institute of Physiology II of the University Hospital Bonn has discovered together with colleagues that the ASC protein. The research team hopes to identify new targets for future therapeutic strategies. The study, published in the Journal of Clinical Investigation, lays the foundation for upcoming clinical trials.
View entry

Back to the news overview